Home
overview

SMi Group announces the 10th Annual RNA Therapeutics Conference in London on February 20th - 21st  2019. Undoubtedly the field of RNA therapeutics is currently undergoing a major expansion, and the potential for using RNA drugs for personalised medicines and immunotherapy, as well as to address genetic, infectious and chronic diseases will ensure the continued development of RNA therapeutics for years to come.

Fulfilling the potential of genetic discoveries requires the development of therapeutics that can specifically modulate the expression of disease-relevant genes. RNA-based drugs, including siRNAs and antisense nucleotides, are promising examples of a newer class of biologics. Researchers have tried to overcome the major challenges for utilising RNAs in a therapeutic context, including: intracellular delivery, stability and immunogenicity.

Join us in February 2019, as SMi’s RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to discuss the challenges for clinical translation of RNA-based therapeutics, with an emphasis on recent advances in delivery technologies, and present an overview of the applications of RNA-based drugs for modulation of gene and protein expression, and genome editing

Networking Opportunities: We keep networking at the forefront when it comes to our events. With 7+ hours of networking included in the event, there will be multiple opportunities to interact with the key industry leaders within the RNA Therapeutics, to benefit your company and develop your career.

The Agenda: A valuable time is spent on the programme and industry, all to provide the best possible agenda for our attendees. Discover the latest trends and hottest topics this 2018.

Location/Venue: Being held in the heart of London, Holiday Inn Kensington Forum is perfectly located to explore London from.

Onsite: Our knowledgeable events team onsite staff will provide you with an exceptional service. They will answer any questions you may have and inform you about any changes to the agenda, to ensure the event runs smoothly.
 

Key Job Titles include:

Research & Development Directors/Managers/Scientists
Senior Scientists
Chief Scientific Officers
Chief Medical Officers
Heads of Clinical Development
Heads of Pre-Clinical Development
 

Global Presence:

Attendees from all over the world attend our events, gain hands on insight from representatives from UK, Europe and USA.

Companies include:

Admedus Immunotherapies | AstraZeneca | Bayer AG | BioNTech | CureVac | Diamond Biopharm | Dicerna Pharmaceuticals | Exicure Inc. | Exiqon | GlobalAcorn Ltd | GSK | Imperial College London | Lipocalyx | Merck | MHRA | Mundipharma International Ltd | Novartis Institutes for Biomedical Research | Quark Pharmaceuticals Inc. | Roche A / S | Sanofi | Silence Therapeutics GmbH | Silenseed | SilverRNA | Storm Therapeutics | ThermoFisher | Valneva | Yuria Pharma
 

Admedus Immunotherapies; AstraZeneca; Bayer AG; BioNTech; BioNTech AG; C B M C N R S; Carpmaels & Ransford; Centre de biophysique molÚculaire; Cydan; Diamond Biopharm; Exicure Inc.; Exiqon; GlobalAcorn Ltd; GSK; Heptares Therapeutics; Imperial College London; Lipocalyx; Merck Sharp & Dohme; MHRA; Mundipharma International Ltd; NOF CORPORATION; Novartis Institutes for Biomedical Research; Quark Biotech Inc; Quark Pharmaceuticals Inc.; Roche A / S; Roche Diagnostics Deutschland GmbH; Roche Innovation Center Shanghai; Royal College of Surgeons, Ireland; Ryboquin Company Ltd; Silence Therapeutics GmbH; Silenseed; SilverRNA; TCR Solutions; The Italian Institute of Technology; ThermoFisher; UCB BioPharma SPRL; Universita Magna Graecia - Catanzaro; University of Eastern Piedmont; University Of Twente / 20Med; Valneva; Yuria Pharma;

FEATURED SPEAKERS

Andre Gerber

Andre Gerber

Professor, RNA Biology, University Of Surrey
David  Blakey

David Blakey

Chief Scientific Officer, MiNA Therapeutics
David Giljohann

David Giljohann

CEO, Exicure Inc.
Ekkehard Leberer

Ekkehard Leberer

Senior Director , Sanofi-Aventis Deutschland GmbH
Jeffrey Ulmer

Jeffrey Ulmer

Head Preclinical R&D, GSK
Marian Gindy

Marian Gindy

Executive Director, Merck & Co.
Markus  Mandler

Markus Mandler

Chief Scientific Officer, Accanis Biotech F&E GmbH & Co KG
Paul Agris

Paul Agris

Director, The RNA Institute
Shalini  Andersson

Shalini Andersson

Senior Director and Head of New Modalities, Cardiovascular, Renal and Metabolism , AstraZeneca
Troels Koch

Troels Koch

Vice President & Head of Research, RNA Therapeutics, Roche Innovation Center Copenhagen

Andre Gerber

Professor, RNA Biology, University Of Surrey
Andre Gerber

André studied Biochemistry at the University of Zurich and obtained a PhD in Cell Biology from the University of Basel for his work on adenosine deaminases acting on RNA. He completed post-doctoral studies at Stanford University, where he started to explore RNA-protein interactions on a global scale. During 2004-2011, he was an independent research group leader at the ETH Zurich, further investigating RNA-protein interaction networks with genomics and proteomics means in different model organisms. Since 2012, he is Professor of RNA biology at the Faculty of Health and Medical Sciences, University of Surrey, UK.

Bob Brown

Chief Scientific Officer, Senior Vice President, Dicerna Pharmaceuticals Inc.
Bob Brown

David Blakey

Chief Scientific Officer, MiNA Therapeutics
David  Blakey

I have a degree in Biochemistry from Oxford University, a PhD from London University and then worked as a Post Doc at the ICRF in London. In 1987 I joined AstraZeneca where I championed the company’s move into therapeutic antibodies and led the collaboration that developed Imfinzi.
 

I was appointed Chief Scientist in Oncology in 2008 and in my last 4-5 years at AstraZeneca I led a global cross therapy area team on oligonucleotide-based therapies. In October 2015, continuing my career in Oligonucleotide Therapeutics, I joined MiNA Therapeutics as their CSO and lead research on their small activating RNA platform.
 

David Giljohann

CEO, Exicure Inc.
David Giljohann

Dr. Giljohann has served as CEO of Exicure since 2013. Dr. Giljohann obtained his Ph.D. in 2009 from Northwestern University under the direction of Dr. Chad A. Mirkin where he developed oligonucleotide-modified nanoparticles, including NanoFlare™, and Spherical Nucleic Acid (SNA™) constructs. Dr. Giljohann has contributed to over 25 manuscripts and over 100 patents and applications.

Ekkehard Leberer

Senior Director , Sanofi-Aventis Deutschland GmbH
Ekkehard Leberer

Dr. Leberer received his Ph.D. in Biology at the University of Konstanz, Germany (1986). He conducted post-doctoral training in molecular biology at the Banting and Best Institute of the University of Toronto, Canada, and then became a Professor of Biochemistry at the University of Konstanz, Germany (1992). He is currently responsible for R&D Alliance Management at Sanofi, and is the Scientific Managing Director of the Innovative Medicine Initiative COMPACT Consortium on the delivery of biopharmaceuticals across biological barriers and cellular membranes (www.compact-research.org).
Since joining Hoechst Marion Roussel in 1998, Dr. Leberer carried out various managing roles in this company, Sanofi’s predecessor companies and Sanofi itself, including responsibilities in functional genomics, biological sciences and external innovation for oligonucleotide-based therapeutics. He has also served as Head of Biotechnology Germany and a member of the Scientific Review Committee of Aventis Pharma Germany.
Prior to joining pharmaceutical industry, Dr. Leberer served as Senior Research Officer in genetics and genomics at the Biotechnology Research Institute, National Research Council of Canada, Montreal. His research has focused on the molecular mechanisms of signal transduction and the role of signalling molecules in human diseases. He is the principal discoverer of the p21 activated protein kinase (PAK) family of cell signalling proteins and of novel virulence-inducing genes in pathogenic fungi. He is co-author of more than 60 publications in prestigious peer-reviewed journals including Nature and Science.

 

Hans Kistemaker

Senior Scientist, ProQR
Hans Kistemaker

Henrich Haas

Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
Henrich Haas

Ingmar Hoerr

Founder and CEO, Curevac Ag
Ingmar Hoerr

Jeffrey Ulmer

Head Preclinical R&D, GSK
Jeffrey Ulmer

Dr. Jeffrey Ulmer received his B.Sc. with honors from the Department of Chemistry at the University of Regina and was the recipient of the Merit Award of the Society of Chemical Industry of Canada. He received his Ph.D. in biochemistry from McGill University and completed his postdoctoral training in the laboratory of Nobel laureate Dr. George Palade in the Department of Cell Biology at Yale University School of Medicine. At Merck Research Laboratories, Chiron Corporation and Novartis Vaccines he conducted seminal studies on nucleic acid vaccines and novel vaccine adjuvants/delivery systems. He has published over 200 scientific articles and is an inventor on 11 patents. Dr. Ulmer is on the editorial boards of Expert Opinion on Biological Therapy, Human Vaccines, and Expert Review of Vaccines, and serves on several external scientific advisory boards and committees. During his 28 year career in vaccines R&D, his leadership roles and responsibilities have included: Platform Technology Leader (DNA, RNA vaccines), Project Leader (Tuberculosis, SARS), Department Head (Immunology & Cell Biology), US Site Head for Research, and Global Function Head (External Research). He is currently Head, Preclinical R&D, GSK Vaccines, where he leads a diverse team of scientists in the discovery and development of viral and bacterial vaccines, and technology innovation.

Marian Gindy

Executive Director, Merck & Co.
Marian Gindy

Marian Gindy is Executive Director, Discovery Pharmaceutical Sciences at Merck & Co., Inc., leading a group responsible for drug product design and early development across therapeutic areas and drug modalities, including mRNA vaccines. Previously, Dr. Gindy served as Director and Head of Sterile Product Development at Merck with responsibility for definition of formulations and manufacturing processes for parenteral products, from preclinical stages to Phase 3. Earlier, Dr. Gindy was Director and Head of RNA Therapeutics Formulation Sciences, where she led discovery and development research, and process capability build, for specialty formulation, drug delivery and manufacturing technologies for siRNA therapeutics. Marian has additionally held leadership roles in drug substance process development and pilot plant operations. Dr. Gindy received her Ph.D. in Chemical and Biological Engineering from Princeton University

Markus Mandler

Chief Scientific Officer, Accanis Biotech F&E GmbH & Co KG
Markus  Mandler

Dr. Mandler is CSO of ACCANIS, bringing with him over 10 years of collaborative research and management experience spanning academia and industry. He completed his PhD at Boehringer Ingelheim´s Institute of Molecular Pathology in Vienna in 2003 working on skin development and especially focused on appendages including hair, feathers, and teeth. Dr. Mandler is the former head of the Neurodegeneration Department at AFFiRiS where he was responsible for developing several immunotherapeutics from preclinic into early clinical development. He has authored numerous publications in high impact journals, several patents and has received multiple national and international research grants for his work.

Paul Agris

Director, The RNA Institute
Paul Agris

Paul Agris founded The RNA Institute, a global alliance of top RNA biomedical researchers creating tools for RNA applications. Formerly, Agris was Head of NCSU’s Department of Biochemistry and founded and led the RNA Society of North Carolina for more than a decade. He was an Assistant, Associate and full Professor in the Division of Biological Sciences and Department of Medicine at the University of Missouri-Columbia. Agris received his graduate degree from MIT, and was a postdoctoral fellow at Yale. For over 50 years, he has conducted funded RNA science leading to publications, patents and the founding of two companies.

Shalini Andersson

Senior Director and Head of New Modalities, Cardiovascular, Renal and Metabolism , AstraZeneca
Shalini  Andersson

Shalini is Senior Director and Head of Drug Metabolism & Pharmacokinetics within the Cardiovascular and Metabolic Disease Innovative Medicines unit (CVMD IMED) since December 2010. She is also a member of the Management Team for CVMD IMED as well as of the Review Board for CVMD drug projects. Currently Shalini is also leading Targeted Drug Delivery within CVMD therapy area including the open innovation collaboration with IONIS Pharmaceuticals. She is also the project leader for subcutaneous delivery of modified RNA to man.
Shalini received her PhD in 1989 at the University of Linköping, Sweden and was a research fellow at the Institute of Pharmaceutical Chemistry, University of Münster, Germany. She joined AstraZeneca in 1997.She is the author or co-author of over 34 peer reviewed articles, 2 book chapters and 4 patents.
 

Troels Koch

Vice President & Head of Research, RNA Therapeutics, Roche Innovation Center Copenhagen
Troels Koch

Troels Koch (TK) is Ph.D. in bio-organic chemistry and has worked in the area of nucleic acid chemistry and biology for 20 years. TK is a founder of several Biotech companies of which Exiqon A/S and Santaris Pharma A/S are the most commonly known. Santaris Pharma A/S has pioneered the proprietary LNA platform and contributed significantly to the field of RNA-therapeutics. Santaris Pharma A/S was in August 2014 acquired by Roche, and TK is presently VP & Head of Research at Roche Innovation Centre Copenhagen. The main responsibilities are to develop the fundamental understanding of the chemical and biological properties of LNA, improve and upgrade the LNA platform, refine the LNA antisense drug discovery process, and establish a RNA therapeutics drug pipeline in Roche. During his academic and biotech career, TK has gained significant experience in managing R & D activities, intellectual property, regulatory affairs, antisense drug substance/product manufacturing, and nucleic acid bio-organic chemistry.

VENUE

Copthorne Tara Hotel

Scarsdale Place, Kensington, London, United Kingdom

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

SAVE TO


Outlook Calendar  OUTLOOK CALENDAR
Google Calendar  GOOGLE CALENDAR
ICal Calendar  ICAL CALENDAR
Yahoo! Calendar  YAHOO! CALENDAR

Copthorne Tara Hotel

Scarsdale Place
Kensington
London W8 5SR
United Kingdom

Copthorne Tara Hotel

The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

 

HOTEL BOOKING FORM

Title

SubTitle
speaker image

Content


Title


Description

Download


WHAT IS CPD?

CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

CPD AND PROFESSIONAL INSTITUTES

There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

GLOBAL CPD

Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

CPD Certificates

We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

Event Title

Headline

Text
Read More

I would like to speak at an event

I would like to attend an event

I would like to sponsor/exhibit at an event

SIGN UP OR LOGIN

Sign up
Forgotten Password?

Contact SMi GROUP LTD

UK Office
Opening Hours: 9.00 - 17.30 (local time)
SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
Registered in England No: 3779287 VAT No: GB 976 2951 71




Forgotten Password

Please enter the email address you registered with. We will email you a new password.

Thank you for visiting our event

If you would like to receive further information about our events, please fill out the information below.

By ticking above you are consenting to receive information by email from SMi.
Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out